Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

ABSTRACT:

Background

In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed consistent favourable, although non-significant, effects on carotid intima-media thickness (CIMT) progression at 48 weeks. We hereby communicate planned final 96 week results on biomarker changes and CIMT progression.

Methods

PWH on a PI/r-based triple therapy regimen were randomly assigned (1:1) to switch the PI/r component to dolutegravir either immediately (DTG-I group) or after 48 weeks (DTG-D group) and were followed up to 96 weeks. We assessed changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin res

SUBMITTER: Gonzalez-Cordon A 

PROVIDER: S-EPMC7617418 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature